The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) located within National Cancer Center, Singapore (NCCS) is home to a state-of-the-art facility. This facility comprises of a current Good Manufacturing Practice (cGMP) Facility and a Good Tissue Practice (GTP) Facility, dedicated to meeting the growing demand for process development and manufacturing of cell, tissue, and gene therapy (CTGT) products, alongside related translational research in Singapore and the broader ASEAN region.
The facility envisions to house state-of-art technologies that will enable manufacturing of CTGT products to serve both the public and private sector of Singapore.
The facility aims to attain all national level certifications/accreditations that will be administered by Health Science Authority and Ministry of Health, Singapore with regards to CTGT manufacturing. ACTRIS will also aim to meet
CTGT manufacturing standards set by international organisations and regulatory authorities such as FDA, PIC/S, EMA, and ISCT.